Serge Saxonov - 08 Feb 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
08 Feb 2022
Net transactions value
-$1,043,909
Form type
4
Filing time
10 Feb 2022, 16:46:22 UTC
Previous filing
06 Jan 2022
Next filing
24 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $34,876 +3,038 +0.33% $11.48* 925,293 08 Feb 2022 Direct F1
transaction TXG Class A Common Stock Sale $79,349 -900 -0.1% $88.17 924,393 08 Feb 2022 Direct F1, F2
transaction TXG Class A Common Stock Sale $374,590 -4,200 -0.45% $89.19 920,193 08 Feb 2022 Direct F1, F3
transaction TXG Class A Common Stock Sale $406,618 -4,503 -0.49% $90.30 915,690 08 Feb 2022 Direct F1, F4
transaction TXG Class A Common Stock Sale $218,228 -2,397 -0.26% $91.04 913,293 08 Feb 2022 Direct F1, F5
holding TXG Class A Common Stock 4,138 08 Feb 2022 See footnote F6
holding TXG Class A Common Stock 89,960 08 Feb 2022 See footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -3,038 -6.7% $0.000000 42,521 08 Feb 2022 Class A Common Stock 3,038 $11.48 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $87.64 to $88.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $88.66 to $89.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $89.76 to $90.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $90.765 to $91.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F7 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F8 This option, originally for 145,786 shares, of which 103,265 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.